Cardiovascular effects of glucagon-like peptide 1 receptor agonists.
Event: ESC Congress 2021 - The Digital Experience
Topic: Risk Factors and Prevention
Session: Exploring the latest evidence of cardiovascular benefits with glucagon-like peptide 1 receptor agonists
GLP-1 and the cardiovascular system
Event: ESC Congress 2019
Topic: Diabetes and the Heart
Session: GLP-1 Receptor agonists – Pioneers of further cardiovascular risk reduction in diabetes?
Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events
Event: ESC Congress 2018
Topic: Pharmacotherapy
Session: Diabetes, adiposity and metabolic syndrome
Connect with the speakers: questions & answers.
Event: ESC Congress 2018
Topic: Diabetes and the Heart
Session: Joining clinical practices: cardiovascular disease and type 2 diabetes
Aligning treatment barriers with practical considerations.
Event: ESC Congress 2018
Topic: Diabetes and the Heart
Session: Joining clinical practices: cardiovascular disease and type 2 diabetes
Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?
Event: ESC Congress 2017
Topic: Diabetes, dysglycaemia and metabolic syndrome
Session: GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
Results from the LEADER cardiovascular outcomes trial.
Event: ESC Congress 2017
Topic: Diabetes, dysglycaemia and metabolic syndrome
Session: GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
Cardiovascular outcomes trials in diabetes – What have we learned?
Event: ESC Congress 2016
Topic: Diabetes management
Session: Addressing cardiovascular risk in type 2 diabetes - The LEADER trial
ESC 365 is supported by
